Korea Development Bank's Proposed Senior Unsecured Samurai Bonds Rated 'A' Oct 11

  • ID: 1929333
  • October 2011
  • Standard & Poors
1 of 3


  • Korea Development Bank
  • MORE

MUMBAI (Standard & Poor's) Oct. 4, 2011--Standard & Poor's Ratings Services said today that it has assigned its 'A' rating to Korea Development Bank's (KDB; A/Negative/A-1) proposed senior unsecured samurai bonds. The rating on the unsecured debt is subject to final documentation. KDB intends to use the bond proceeds for repayments of medium- and long-term foreign-currency-denominated debts and the bank's operating activities. The notes will constitute direct, unconditional, unsecured, and unsubordinated obligations of the bank. They will rank pari passu with all other unsecured and unsubordinated obligations of the bank. RELATED CRITERIA AND RESEARCH Bank Rating Analysis Methodology Profile, March 18, 2004 Rating Government-Related Entities: Methodology And Assumptions, Dec. 9, 2010 A Korean-language version of this media release is available...

Companies mentioned in this report are:
- Korea Development Bank

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Korea Development Bank

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.